Screnning of viral hepatitis in mental disorder patients: Psiqui-Clinic Programme. (1st June 2022)

• Record Type: Journal Article
• Authors: Cavero, M.; Planas, T.; Goikolea, J.; Lens, S.; Bartrés, C.; Colomer, L.; García, C.; Valentí, M.; Ruiz, V.; Rivas, Y.; Benabarre, A.; Catalan, R.; Masana, G.; Colom, J.; Forns, X.; Martin-Santos, R.; Mariño, Z.
• Is Part Of: European psychiatry. Volume 65:Supplement 1(2022)
• Page Start: S480
• Page End: S481
• Publication Date: 2022-06-01
• Subjects: viral hepatitis -- HCV -- Severe Mental Disorders -- HBC; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2022.1221
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract : Introduction: The WHO would increase diagnosis and treatment of viral hepatitis in the world by 2030, based on the high efficacy of direct-acting-antivirals against HCV, extended vaccination programs in HBC, and epidemiological data. Diagnostic of HCV/HBV infection has been simplified by point-of-care (POC) devices (cheap/easy-to-use/interprete/qick-results), detecting anti-HCV-antibodies or HBV-antigen in capillary blood at the patients´site. The current seroprevalence of viral hepatitis B/C in general population in Spain is 0.5%/1% and would be higher (3-17%) in people with severe-mental-disorder due to risk factors and traditionally less access to health care. Objectives: To design a screening protocol for HCV eradication and HBV-detection, and risk factors among severe-mental-disorder patients in a CommunityMentalHealthCenter. To guarantee equal access to viral hepatitis screening and therapy among this population. Methods: Outpatients visited along one-year who accepts participate. Using POC-device for qualitative detection of anti-HCV-antibodies (Quickview-of-Lumiquick-Diagnostics®)/HBsAG (Abbott-Rapid-Diagnostics®). Socio-demographic data; mental disorder(ICD-10); HCV/HBV risk-factors; Neurotoxicity-scale (mood/cognition/sleep/gastrointestinal/sickness/motor); SF-12; Patient-satisfaction. Subjects with positive HCV/HBV POC-test will have a on-site venopuncture to assess hemograme/liver tests, and HCV-RNA (Cobas-TaqMan-RocheDiagnostics)/HBsAg-ELISA (Atellica-Siemens). In positive HCV-RNA (active infection) the psychiatric-team will inform the hepatology-team for non-invasive liver fibrosis assessment and DAA prescription. The patient will receive 8-12-weeks on-site treatment, and assessed (Neurotoxicity/SF-12).HCV cure will be confirmed by HCV-RNA in blood. Chronic-cases will be managed at Hepatology-Unit. Results: We will present the results of the implementation of the programme and their ability to detect viral-hepatitis-positive cases among patients with severe-mental-disorders and to treat them effectively. Conclusions: Our results may support the generalisation of the programme in among CMHC's. Disclosure: No significant relationships.